Novo Nordisk A/S Q4 FY2024 earnings call

Key managerial messages and operational highlights:

• Purpose and Sustainability: Served over 45 million patients, expanded women in senior leadership to 42%, and carbon emissions rose 23% due to increased production and capex.
• Commercial Execution: Total sales up 26%, with North America up 30% and International up 19%. GLP-1 diabetes care sales in US up 24%, Wegovy global sales up 86%, and rare disease sales up 9%.
• R&D Highlights: CagriSema Phase III results, semaglutide 7.2mg Phase III data, amycretin Phase Ib/IIa results, and upcoming R&D milestones including submissions and trial initiations.
• Financials: Sales grew 26% at constant exchange rates, gross margin at 84.7%, R&D costs up 48%, and DKK 64.3B returned to shareholders via dividends and share buyback.

In 2024, Novo Nordisk achieved 26% sales growth and 26% operating profit growth. Segment performance:

• Diabetes and Obesity Treatments: Served over 45 million patients, an increase of nearly 4 million from the previous year. GLP-1 sales in diabetes increased by 22%, insulin sales by 17%, obesity care sales by 57%, and rare disease sales by 9%.
• North America Operations: Sales grew 30%. GLP-1 diabetes care sales in the US increased by 24%, Wegovy sales globally grew 86% (59% in North America), and rare disease sales grew 20%.
• International Operations: Sales grew 19%. GLP-1 diabetes care sales increased by 18%, obesity care sales grew 107%, and rare disease sales remained unchanged.

Novo Nordisk's 2025 guidance: Sales growth expected 16%-24% at constant exchange rates. Operating profit growth projected at 19%-27% at constant exchange rates. CapEx expected ~DKK 65 billion, with free cash flow estimated at DKK 75 billion to DKK 85 billion.

Risks include supply chain uncertainties, competition impacts, regulatory changes (e.g., IRA negotiations), and potential effects of compounding pharmacies on demand.

Q: On Wegovy U.S. prescriptions, what's holding back and growth outlook?

A: Dave Moore discussed market expansion, prescription trends starting at ~100k and ending at over 200k, and ongoing scaling efforts.

Q: How does CagriSema's profile stack up vs Zepbound?

A: Martin Lange mentioned REDEFINE 4 trial, with first test being non-inferiority and second test for superiority.

Q: On supply vs competition, how competitive is Novo Nordisk?

A: Karsten Knudsen stated Novo Nordisk scaled patient reach by nearly a factor of 3 over 3 years and expects sales growth in 2025 to reflect strong scaling.

Q: On oral semaglutide 25mg launch, what's the value proposition?

A: Camilla Sylvest discussed the value of an oral segment for obesity, leveraging semaglutide's efficacy and providing optionality.

Q: On REDEFINE 1 dose response, explain patient subgroups?

A: Martin Lange explained two distinct patient subgroups: those titrating to full dose with substantial weight loss and early responders who down-titrated but still achieved significant weight loss.

Q: Impact of IRA on Novo Nordisk?

A: Dave Moore noted semaglutide-containing products are in CMS negotiations, with channel mix being ~50% commercial, 30% Medicare, etc.

Q: On monlunabant in diabetic kidney disease, what's the outlook?

A: Martin Lange stated monlunabant has weight loss potential and comparable safety profile, with focus on exploring further in Phase IIb.

Q: What's the ideal product profile?

A: Lars Jørgensen discussed importance of weight loss percentage, quality of weight loss, and impact on comorbidities, emphasizing a patient-centric, individualized approach.

Q: On REDEFINE 1 patient down-titration, what's the dropout rate?

A: Martin Lange mentioned CagriSema had a 3.6% dropout due to gastrointestinal issues, lower than semaglutide's 4.5% in prior trials.

Q: On amycretin progression, status of Phase III?

A: Martin Lange stated amycretin data meets FDA draft guidance spirit, with ongoing discussions with regulators on next steps.

Q: On LOE for semaglutide, impact on portfolio?

A: Camilla Sylvest stated no radical changes to portfolio positioning, focusing on broad portfolio to address different segments.

Q: On amycretin tolerability vs CagriSema?

A: Martin Lange said amycretin has similar safety and tolerability potential to CagriSema, leveraging combination biology for full potential.